Valion Bio enters Letter Agreement with 3i, LP
Valion Bio, Inc. (Valion Bio) entered into a Letter Agreement with investor 3i, LP regarding Series B Preferred Purchase terms. The market relevance is that the company is facilitating continued capital raises by its largest shareholder and investor.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed